This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Antiobesity medications are considered to be 'vanity drugs' by many private insurers, and the refusal to cover obesity treatment is counterproductive because of obesity's many health consequences.
Joe McKamey, general manager at Marcrom’s Pharmacy, highlights the potential pitfalls or misconceptions that pharmacies may encounter when opening a Medicare-focused insurance agency.
Insurance complications As more information emerges about real-world outcomes for GLP-1s, insurers are paying close attention. With a list price of around $1,000 per month for both Lilly and Novo’s pen injectables, insurers haven’t been willing to offer widespread coverage due to the expense.
Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana.
Joe McKamey, general manager at Marcrom’s Pharmacy in Manchester, Tennessee, talks about why pharmacies should open their own Medicare-focused insurance agency and what steps and preparations they can take to ensure a successful launch and operation.
Right now, anyone with health insurance — adults and children alike — who wants a vaccine that is recommended by the Advisory Committee on Immunization Practices can get it for free. That would create serious financial problems for people, researchers and consumer advocates say.
A survey of more than 5,000 Americans conducted with Ipsos found that nearly 40% of insured Americans struggle to understand what their health insurance covers.
The Patient Experience Survey (PES) series continues to reveal how health insurance is not working as it should for too many Americans — especially vulnerable groups.
Innovation in the vaccine area continues. In 2023, the FDA approved six vaccines, including several important firsts. But they face a difficult landscape where federal policies dictate coverage.
The conglomerate set aside $448 million in the first quarter to cover medical claims from ACA members that won’t be covered by insurance premiums. CVS expects to lose up to $400 million this year in its ACA plans. Continue to STAT+ to read the full story…
This schedule also helped dictate insurance coverage of those recommended vaccines. Drug Topics: How do ACIP recommendations affect broader aspects of vaccine access and utilization, such as insurance reimbursement or public health programs?
Insurers and pharmacy benefit managers (PBMs) continue to shift more and more costs to patients. For seniors who rely on Medicare Part D, the out-of-pocket costs for medicines can sometimes be a barrier. And a new analysis from the Medicare Payment Advisory Commission (MedPAC) shows why this is a problem that must be addressed.
Specifically, HCPs raised concerns over how pharmacy benefit managers (PBMs) and insurers inappropriately use utilization management tools, like prior authorization, to deny or delay care, ultimately harming the patient and impacting patient access to care.
A survey of more than 5,000 Americans conducted with Ipsos found that 30% of insured Americans say they face a financial barrier to care, such as unaffordable out-of-pocket costs or a lack of savings to pay for emergency or unforeseen expenses.
The National Rosacea Society found that a lack of health insurance or the high cost of a copay caused 52% of respondents to avoid obtaining medical care for their rosacea.
Half of every dollar spent on medicines goes to entities that don’t make medicine—like pharmacy benefit managers (PBMs) and insurers who are aggressively consolidating their control over health care and hospitals, clinics and for-profit pharmacies in the 340B markup program.
A proposed Senate bill that would prohibit companies that control health insurers or pharmacy benefit managers from owning pharmacies rattled investors on Wednesday, but some Wall Street analysts believe the legislation is unlikely to gain much traction, at least for now.
She warned that changes in vaccine recommendations could impact insurance coverage, patient access, and ultimately public health, particularly for vulnerable populations like low-income children.
The Department of Justice is investigating Semler Scientific for possible violations of a federal anti-fraud law related to its marketing of a product known as QuantaFlo, a test used in the diagnosis of peripheral artery disease by UnitedHealth Group and other large insurers.
Social determinants of health (SDOH), such as financial disparities or lack of insurance, create barriers to accessing breakthrough therapies like BTK inhibitors among patients with CLL and SLL.
Pharmaceutical’s weight loss pill described as ‘underwhelming’, also piling pressure on share price AstraZeneca shares tumbled on Tuesday wiping £14bn off the value of Britain’s biggest drug maker, after a report that dozens of senior executives at its China unit could be implicated in an insurance fraud case in the country’s pharmaceutical sector.
Fortunately, many insurance plans help cover the cost of Adderall. Ultimately, the persons out-of-pocket price for Adderall depends on several factors set by the insurance provider. Does insurance cover Adderall? Khurana says that health insurance plans are more likely to cover generic drugs when a generic version is available.
A recent study found that Infants younger than 3 months, those born prematurely, and those who were publicly insured were at a higher risk for intubation.
Iowa's Department of Health and Human Services, which manages the two health insurers that delivered care to adults and children in the state’s Medicaid program last year, was alleged to provide inadequate mental and behavioral health care to children on Medicaid.
The average annual healthcare spending for people with employer-sponsored insurance spending increased from $5,630 in 2020 to $6,467 in 2021. After decreasing in 2020, per person healthcare spending increased 15%.
A new CDC report on data collected by the Maternal and Infant Network to Understand Outcomes Associated with Medication for Opioid Use Disorder During Pregnancy, indicates that medication for opioid use disorder is more often given to individuals who are White, older, and have private insurance.
There is only one place in the health care system where middlemen refuse to share negotiated prices with patients, and that’s at the pharmacy counter. A new report reveals how this harmful tactic leads to higher costs for patients.
Bonjesta costs about $490 without insurance for 30, 20-20 mg extended- release tablets. How much does Bonjesta cost without insurance? The copays for Bonjesta, with insurance and Medicare, vary by plan. Drug costs may be affected by differences in insurance plans and specific drug formularies. RELATED: What is Bonjesta ?
would force the companies that own health insurers or PBMs to divest their pharmacy businesses within three years. Federal Trade Commission , The Wall Street Journal reports. A Senate bill, sponsored by Sens. Elizabeth Elizabeth Warren (D-Mass.) and Josh Hawley (R-Mo.),
Although most insurance plans cover medications for opioid use disorder (OUD) to some degree, that coverage varies by formulation and dosage. Here’s what you should know if you need to budget for the cost of buprenorphine without insurance. How much does buprenorphine cost without insurance? mL of 300 mg/1.5 mL of 300 mg/1.5
Brian Rakers, senior vice president of distribution and member support at Pharmacists Mutual Insurance Group, talked cybersecurity during a session at AAP 2024.
For a decade and a half, Americans have been guaranteed that no matter their health insurer, certain preventive care like cancer screenings are free of charge. That’s because an Affordable Care Act provision has required insurers to fully cover services given an A or B recommendation by an expert task force.
The CDC has updated its COVID-19 vaccine guidance for children and pregnant individuals, sparking a debate among health experts and concerns over insurance coverage.
How much does Veozah cost without insurance? The average cost of Veozah without insurance is about $762 per bottle of 30, 45 mg tablets without insurance. The listed price without insurance references the price of brand-name drugs (unless otherwise specified). Is Veozah covered by insurance? gm of 0.75 gm of 0.75
Without insurance, one 40 gm tube of fluorouracil 5% topical cream costs about $363. How much does fluorouracil cost without insurance? Your cost for fluorouracil may vary depending on your diagnosis, treatment regimen, length, and insurance coverage. Without insurance, it can cost around $233 for a single 40 g tube of cream.
How much does diltiazem cost without insurance? Without insurance, there is no health plan formulary to restrict your choices. The listed price without insurance references the price of brand-name drugs (unless otherwise specified). As a result, they are typically among the preferred options on health insurance formularies.
Without insurance, the average retail price of Actos is $2,111 for 90, 30 mg tablets. How much does Actos (pioglitazone) cost without insurance? Without insurance, the price of Actos can vary depending on the quantity, dosage, and pharmacy you purchase the drug from. Without insurance, Actos costs $2,111 for 90, 30 mg tablets.
The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access to drugs that the organization had reviewed for cost effectiveness in 2022.
To further understand PBM market concentration, researchers separately analyzed commercial insurance, Medicare Part D, and Medicaid managed care market strategies of the 3 biggest PBMs.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content